Zymeworks Inc (ZYME)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Kenneth H. Galbraith
Employees:
460
108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
206-337-1030

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

View SEC Filings from ZYME instead.

View recent insider trading info

Zymeworks Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ZYME (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ZYME

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-04-10 by MILLER DEREK JOHN MICHAEL
  • 3: filed on 2023-04-10 by MILLER DEREK JOHN MICHAEL
  • 4: filed on 2023-03-30 by ECOR1 CAPITAL, LLC
  • 4: filed on 2023-03-14 by KLOMPAS NEIL A
  • 4: filed on 2023-01-23 by ECOR1 CAPITAL, LLC
  • 4: filed on 2023-01-18 by ECOR1 CAPITAL, LLC
  • 4: filed on 2023-01-12 by ECOR1 CAPITAL, LLC
  • 4: filed on 2022-12-23 by GALBRAITH KENNETH
  • 4: filed on 2022-12-23 by SACKS NATALIE
  • 4: filed on 2022-12-23 by MAHONY SUSAN

    • Events (8k)

  • 8-K: filed on 2022-10-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-18:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2022-10-11:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-22:
    Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CAMPOY CARLOS

    • Director
    		 0 2023-06-30 2

    ECOR1 CAPITAL, LLC

    • 10% Owner
    		 13,437,473 2023-06-16 6

    MILLER DEREK JOHN MICHAEL

    • Director
    		 0 2023-04-10 2

    KLOMPAS NEIL A PRESIDENT & COO

    • Officer
    		 17,732 2023-03-10 2

    GALBRAITH KENNETH CHAIR & CEO

    • Officer
    • Director
    		 358,000 2023-01-05 2

    ASTLE CHRISTOPHER SVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 78,500 2023-01-05 3

    MOORE PAUL ANDREW CHIEF SCIENTIFIC OFFICER

    • Officer
    		 129,000 2023-01-05 1

    RENTON HOLLINGS

    • Director
    		 25,000 2022-12-21 1

    ZOTH LOTA S.

    • Director
    		 25,000 2022-12-21 1

    MAHONY SUSAN

    • Director
    		 25,000 2022-12-21 1

    NEU KELVIN

    • Director
    		 25,000 2022-12-21 1

    HILLAN KENNETH J.

    • Director
    		 25,000 2022-12-21 1

    SACKS NATALIE

    • Director
    		 25,000 2022-12-21 1

    COX TROY

    • Director
    		 25,000 2022-12-21 1

    JOSEPHSON NEIL CHIEF MEDICAL OFFICER

    • Officer
    		 26,221 2022-11-10 3

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    		 6,045,437 2022-10-13 4

    POLVERINO ANTHONY J. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 36,407 2022-01-07 0

    TEHRANI ALI CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 576,161 2021-07-15 0

    O'DRISCOLL KATHRYN CHIEF PEOPLE OFFICER

    • Officer
    		 6,350 2021-07-06 0

    PRIOUR JAMES CHIEF COMMERCIAL OFFICER

    • Officer
    		 2,513 2021-07-06 0

    HAUSMAN DIANA CHIEF MEDICAL OFFICER

    • Officer
    		 7,377 2021-03-10 0

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    BAKER FELIX

    BAKER JULIAN

    • Director
    		 1,708,472 2020-05-08 0

    BEDFORD NICK

    • Director
    		 0 2019-05-06 0

    POON DAVID KAI YUEN SEE REMARKS

    • Officer
    		 0 2019-05-06 0

    LILLY ELI & CO

    • LESS THAN 10% OWNER
    		 No longer subject to file 2019-01-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ZYMEWORKS INC ZYME 2023-09-25 14:15:04 UTC 2.0578 3.2622 1200000
    ZYMEWORKS INC ZYME 2023-09-25 13:45:04 UTC 2.0361 3.2839 1200000
    ZYMEWORKS INC ZYME 2023-09-25 13:15:04 UTC 2.0361 3.2839 1200000
    ZYMEWORKS INC ZYME 2023-09-25 12:45:06 UTC 2.0361 3.2839 1200000
    ZYMEWORKS INC ZYME 2023-09-22 22:15:03 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 21:45:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 21:15:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 20:45:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 20:15:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 19:45:03 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 19:15:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 18:45:03 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 18:15:04 UTC 2.0361 3.2839 1300000
    ZYMEWORKS INC ZYME 2023-09-22 17:45:04 UTC 0.0 0.0 1300000
    ZYMEWORKS INC ZYME 2023-09-22 17:15:04 UTC 0.0 0.0 1300000
    ZYMEWORKS INC ZYME 2023-09-22 16:45:03 UTC 0.0 0.0 1300000
    ZYMEWORKS INC ZYME 2023-09-22 16:15:04 UTC 0.0 0.0 1300000
    ZYMEWORKS INC ZYME 2023-09-22 15:45:04 UTC 2.0361 3.2839 1200000
    ZYMEWORKS INC ZYME 2023-09-22 15:15:04 UTC 2.0361 3.2839 1200000
    ZYMEWORKS INC ZYME 2023-09-22 14:45:03 UTC 2.0361 3.2839 1200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund ZYME -111.0 shares, $-3937.17 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund ZYME -10.0 shares, $-354.7 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ZYME -90.0 shares, $-3192.3 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ZYME -200.0 shares, $-1728.0 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments